ClinConnect ClinConnect Logo
Search / Trial NCT02542033

Glycemic Response to Low Sugar Apple Juice

Launched by CLINICAL RESEARCH CENTER KIEL GMBH · Sep 3, 2015

Trial Information

Current as of October 13, 2025

Completed

Keywords

Postprandial Glycemia; Apple Juice; Sugar Reduction

ClinConnect Summary

Objectives:

Investigating the effect of sugar reduction in apple juice on glycemic and insulin response to ingestion of this drink.

Subjects/Methods:

In a double-blind randomized placebo-controlled clinical trial with cross-over design 30 male adults with impaired fasting glucose (IFG) received an oral drink of 500mL: 1. Verum: Apple juice, treated (low sugar content); 2. Control: Untreated apple juice (normal sugar content). Capillary blood glucose and venous plasma insulin were measured twice at baseline and then at times 0 (start of drink), 15, 30, 45, 60, 90 and 120 min.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Males aged ≥ 18y
  • 2. diagnosed impaired fasting glucose (IFG)
  • 3. Written informed consent
  • Exclusion Criteria:
  • 1. Subjects currently enrolled in another clinical study
  • 2. Subjects having finished another clinical study within the last 4 weeks before inclusion
  • 3. Hypersensitivity, allergy or idiosyncratic reaction to apple, apple juice or other apple containing food
  • 4. Acute or chronic infections
  • 5. Renal insufficiency
  • 6. Gastrointestinal illness
  • 7. History of gastrointestinal surgery
  • 8. Known fructose intolerance
  • 9. Overt Diabetes mellitus
  • 10. Endocrine disorders
  • 11. Any disease or condition which might compromise significantly the hematopoietic, renal, endocrine, pulmonary, hepatic, cardiovascular, immunological, central nervous, dermatological or any other body System with the exception of the conditions defined by the inclusion criteria
  • 12. History of hepatitis B and C
  • 13. History of HIV infection
  • 14. History of coagulation disorders or pharmaceutical anti-coagulation (with the exception of acetylsalicylic acid)
  • 15. Regular medical treatment including OTC, which may have impact on the study aims (e.g. antidiabetic drugs, laxatives etc.)
  • 16. Major cognitive or psychiatric disorders
  • 17. Subjects who are scheduled to undergo hospitalization during the study period
  • 18. Eating disorders (e.g. anorexia, bulimia) or special diets (e.g. vegan, vegetarian)
  • 19. Present drug abuse or alcoholism
  • 20. Legal incapacity

About Clinical Research Center Kiel Gmbh

Clinical Research Center Kiel GmbH is a leading clinical trial sponsor dedicated to advancing medical research through innovative and rigorous study design. Based in Kiel, Germany, the organization specializes in conducting Phase I-IV clinical trials across various therapeutic areas, leveraging state-of-the-art facilities and a team of highly experienced professionals. With a commitment to ethical standards and patient safety, Clinical Research Center Kiel GmbH collaborates with pharmaceutical and biotechnology companies to facilitate the development of new treatments, while ensuring compliance with regulatory requirements and fostering scientific integrity. Their expertise and comprehensive approach position them as a trusted partner in the clinical research landscape.

Locations

Kiel, Schleswig Holstein, Germany

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials